CA3242449A1 - Use of aminopyrazole compounds - Google Patents

Use of aminopyrazole compounds

Info

Publication number
CA3242449A1
CA3242449A1 CA3242449A CA3242449A CA3242449A1 CA 3242449 A1 CA3242449 A1 CA 3242449A1 CA 3242449 A CA3242449 A CA 3242449A CA 3242449 A CA3242449 A CA 3242449A CA 3242449 A1 CA3242449 A1 CA 3242449A1
Authority
CA
Canada
Prior art keywords
aminopyrazole compounds
jak
compounds
aminopyrazole
atopic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3242449A
Other languages
English (en)
French (fr)
Inventor
Linda HORSPOOL
Timothy Kowalski
Christina Moller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Publication of CA3242449A1 publication Critical patent/CA3242449A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3242449A 2021-12-24 2022-12-23 Use of aminopyrazole compounds Pending CA3242449A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21217736 2021-12-24
EP21217736.4 2021-12-24
PCT/EP2022/087698 WO2023118555A1 (en) 2021-12-24 2022-12-23 Use of aminopyrazole compounds

Publications (1)

Publication Number Publication Date
CA3242449A1 true CA3242449A1 (en) 2023-06-29

Family

ID=79025165

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3242449A Pending CA3242449A1 (en) 2021-12-24 2022-12-23 Use of aminopyrazole compounds

Country Status (9)

Country Link
US (1) US20250049775A1 (https=)
EP (1) EP4452970A1 (https=)
JP (1) JP2024545293A (https=)
KR (1) KR20240124925A (https=)
CN (1) CN118541364A (https=)
AU (1) AU2022418280A1 (https=)
CA (1) CA3242449A1 (https=)
MX (1) MX2024007863A (https=)
WO (1) WO2023118555A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4208157A1 (en) 2020-09-04 2023-07-12 Elanco Us Inc. Palatable formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286640B6 (sk) 1998-06-19 2009-03-05 Pfizer Products Inc. Pyrol [2,3-d] pyrimidínová zlúčenina, jej použitie na výrobu liečiva, farmaceutická kompozícia s jej obsahom, použitie jej kombinácie s ďalšími činidlami a súpravy s jej obsahom na výrobu liečiva
KR101335843B1 (ko) 2008-08-20 2013-12-02 조에티스 엘엘씨 피롤로[2,3-ｄ]피리미딘 화합물
CA2849168A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
WO2014146246A1 (en) 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors
JP7116063B2 (ja) 2016-12-14 2022-08-09 インターベット インターナショナル ベー． フェー． 選択的ヤヌスキナーゼ阻害剤としてのアミノピラゾール類
KR20220119024A (ko) * 2019-12-20 2022-08-26 인터벳 인터내셔널 비.브이. 피라졸 제약 조성물

Also Published As

Publication number Publication date
WO2023118555A1 (en) 2023-06-29
KR20240124925A (ko) 2024-08-19
EP4452970A1 (en) 2024-10-30
AU2022418280A1 (en) 2024-06-13
US20250049775A1 (en) 2025-02-13
CN118541364A (zh) 2024-08-23
JP2024545293A (ja) 2024-12-05
MX2024007863A (es) 2024-08-30

Similar Documents

Publication Publication Date Title
PH12019500932A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
PH12018502472A1 (en) 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
MX389697B (es) Nuevos derivados de pirazolopirimidina.
EP4566675A3 (en) Heterocyclic compounds as immunomodulators
EP4520328A3 (en) Heterocyclic compounds as immunomodulators
WO2020132661A3 (en) Inhibitors of fibroblast activation protein
MX390535B (es) Compuestos de amino-triazolopiridina y su uso en el trataniento del cancer.
MX2020001403A (es) Nuevos derivados de quinolina.
MY198510A (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
HK1255598A1 (zh) 咪唑并[4，5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途
EP3693369A3 (en) Bromodomain inhibitors
WO2018077944A3 (en) 4,5-annulated 1,2,4-triazolones
WO2006094187A3 (en) Phthalazine, aza- and diaza-phthalazine compounds and methods of use
WO2008045393A3 (en) Imidazo- and triazolo-pyridine compounds and methods of use therof
MXPA05009304A (es) Derivados de indol utiles para el tratamiento de enfermedades.
WO2012047587A3 (en) Mdm2 inhibitors for treatment of ocular conditions
UA99524C2 (ru) Триазолопроизводные, полезные для лечения болезней
WO2006058868A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
EP4338802A3 (en) Tyk2 inhibitors, uses, and methods for production thereof
PH12019502365A1 (en) New bicyclic pyrazole derivatives
MX2020001404A (es) Dihidrooxadiazinonas.
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
EP4603148A3 (en) Deuterium-enriched pirfenidone and methods of use thereof

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20240705

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20240828